REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
Deepbridge are pleased to announce that we have sponsored Seb Morris in the Porsche Carrera Cup GB 2022, which continues to be the fastest single marque GT racing series in the country. With its 350th race, the prestigous Porsche Championship returns for its milestone 20th anniversary this year.
Deepbridge are pleased to announce that we have sponsored Louise Burton, a snooker player who is currently ranked 39th in the world by World Women's Snooker and also Administration Executive at Deepbridge.
Louise Burton has competed on the World Women’s Snooker Tour since 2018, most notably reaching the last 16 of her debut event at the Eden Masters.
Sky Medical Technology Ltd., an investee company within the Deepbridge Technology Growth EIS portfolio, announced further U.S. Food and Drug Administration (FDA) 510(k) clearance to market the new (W3) geko™ device variant, for increasing microcirculatory blood flow in lower limb soft tissue of patients with venous insufficiency and/or ischemia.
Filisia, an investee company within the Deepbridge Life Sciences EIS portfolio, has been selected to participate in the 'Play For All Accelerator' by The LEGO Foundation.
The Play For All programme brings together 25 start-ups, non-governmental organisations and social enterprises that support neuro divergent children to grow and thrive through play.
Sky Medical Technology Ltd., an investee company within the Deepbridge Technology Growth EIS portfolio, announced the availability of its flagship product the geko™ device, on the Government of India e-Marketplace (GeM) procurement portal.
As of the 25th April 2022, Deepbridge Capital is proud to announce that it has deployed a record £31.5 million into early-stage technology and life sciences companies during the 2021/22 tax year, up from £29.4 million in 2020/21.
Touch Biometrix, an investee company within the Deepbridge Technology Growth EIS portfolio, has announced a successful Series B funding round, with plans to launch a FAP60 fingerprint biometric sensor as the first prodct utilising its thin transistor film (TFT) technology with 'active pixels'.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]
